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Hepatocyte growth factor regulates proteoglycan synthesis
in interstitial fibroblasts
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Hepatocyte growth factor regulates proteoglycan synthesis in
interstitial fibroblasts.
Background. Hepatocyte growth factor (HGF) is a clinically
important growth factor with therapeutic potential for the
treatment of interstitial fibrosis and chronic renal failure. Pro-
teoglycans are components of the renal interstitium, which have
multiple actions, including growth regulation. In this study, we
examined the effects of HGF on proteoglycan synthesis in
interstitial fibroblasts, and the mechanisms of these effects.
Methods and Results. Expression and agonist-induced acti-
vation of the HGF receptor c-Met was detected in rat renal
interstitial fibroblasts (NRK-49F) by reverse transcription-
polymerase chain reaction (RT-PCR) analysis and immune
complex/immunoblot assay. Moreover, stimulation of the cells
with HGF resulted in a marked increase (five- to tenfold) in
phosphorylation of extracellular signal-related protein kinase
(ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK),
but not of c-Jun NH2 terminal kinase (JNK). Treatment with
HGF resulted in a time- and dose-dependent increase (P 
0.01) in both cell-associated and secreted proteoglycan synthesis
to two- to fourfold of control levels. This effect was attenuated
by the MAPK/ERK kinase (MEK) inhibitor PD98059 and the
p38 MAPK inhibitor SB203580. Ion-exchange chromatography
suggested that chondroitin sulfate/dermatan sulfate proteogly-
cans were up-regulated after HGF treatment. Northern blot,
RT-PCR, Western blot, and promoter activity assays revealed
that HGF caused a significant increase in decorin mRNA and
protein, as well as in biglycan mRNA, protein, and promoter
activity, suggesting transcriptional control of gene expression.
Since the effects of biglycan on fibroblast proliferation are still
unclear, the effects of biglycan were examined by thymidine
assay, and biglycan was found to attenuate transforming growth
factor- (TGF-)–induced changes in cell proliferation.
Conclusion. These results suggest that HGF causes an in-
crease in the small leucine-rich proteoglycans biglycan and
decorin by ERK1/2- and p38 MAPK-mediated pathways in
fibroblasts. These findings may be relevant for understanding
potential mechanisms by which HGF can exert TGF- inhibi-
tory actions in the kidney.
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Recent studies have suggested that hepatocyte growth
factor (HGF) is an important therapeutic candidate for
the treatment of renal disease. HGF is a relatively re-
cently discovered growth factor, which was originally
identified and cloned as a mitogen for mature hepato-
cytes [1]. However, later studies suggested that HGF
also has multiple actions in the kidney, many of which
may be of therapeutic benefit [2–4]. For example, injec-
tion of recombinant HGF into a mouse model of chronic
renal disease was shown to inhibit the onset of tubuloin-
terstitial fibrosis [5]. Similarly, administration of HGF
by injection [6] or by systemic administration of naked
plasmid [7] has been reported to ameliorate chronic renal
fibrosis seen in the unilateral ureteral obstruction model
of interstitial fibrosis, whereas neutralization of endoge-
nous HGF with anti-HGF antibodies produces the oppo-
site effect [6]. A beneficial effect of HGF has also been
found in chronic allograft nephropathy [8]. From these
results emerges the concept that HGF not only plays a
role in the pathogenesis of renal disease, but also may
be useful for the therapy of interstitial fibrosis.
An important objective in nephrology is the develop-
ment of new treatments to arrest and/or reverse the
progression of chronic renal failure. These results from
several laboratories suggest that HGF may indeed hold
promise for the treatment of renal disease, but at present
many of the mechanisms by which HGF can influence
the progression of renal disease are still undefined.
Proteoglycans are important components of the extra-
cellular matrix of the renal interstitium and are known
to fulfill a variety of important functions, including the
control of collagen deposition, and the activation and
inactivation of cytokines and growth factors. In particu-
lar, the proteoglycan decorin is thought to be a natural
inhibitor of transforming growth factor- (TGF-) [9],
and administration of this proteoglycan by injection [10]
or gene transfer [11] has been shown to arrest the pro-
gression of renal disease.
Although proteoglycans play an important role in the
processes of growth and extracellular matrix deposition,
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the effects of HGF on proteoglycan synthesis are unde-
fined. In this study, our aims were to (1) to examine if
HGF receptors are present in fibroblasts, and to under-
stand the signal transduction mechanisms activated by
HGF; (2) to characterize the effects of HGF on proteo-
glycan subtype synthesis in interstitial fibroblasts, and the
mechanisms of these effects; and (3) to examine poten-
tial consequences of the up-regulation of proteoglycans
by HGF. Our results suggest that HGF can up-regulate
growth modulatory proteoglycans, which may be rele-
vant for our understanding of the actions of HGF in the
renal interstitium.
METHODS
Culture of rat renal interstitial fibroblasts (NRK-49F)
and analysis of c-Met mRNA
The rat renal interstitial fibroblast cell line NRK-49F
was obtained from the American Type Culture Collec-
tion, and cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal calf serum
(FCS). Total RNA was purified by the acid guanidine-
phenol-chloroform method [12], then 1 g was subjected
to reverse transcription-polymerase chain reaction (RT-
PCR) analysis for c-Met mRNA using the primers and
protocols described by Oh et al [13]. In some experi-
ments, reverse transcriptase was omitted to ensure the
lack of contamination with genomic DNA. To confirm
that the results were not specific to the NRK-49F cell
line, experiments were also performed using human neo-
natal dermal fibroblast primary cultures [neonatal hu-
man fibroblast (NHF) cells], which were obtained from
Sanko Junyaku (Tokyo, Japan).
Analysis of agonist-induced c-Met phosphorylation
Analysis of agonist-induced c-Met phosphorylation
was performed using an immune complex-immunoblot
analysis technique [14]. In brief, NRK-49F was made qui-
escent by placing it in serum-free DMEM for 48 hours.
The cells were treated with HGF (20 ng/mL) for 5 minutes,
and then reactions were terminated by rinsing with ice-
cold phosphate-buffered saline (PBS), followed by lysis
in immunoprecipitation buffer [50 mmol/L HEPES, 150
mmol/L NaCl, 1% Triton X-100, 1.5 mmol/L MgCl2, 1
mmol/L ethyleneglycol tetraacetate (EGTA), 1 mmol/L
phenylmethylsulfonyl fluoride (PMSF), 1 mg/mL leu-
peptin, 50 mmol/L sodium fluoride, 10 mmol/L sodium
pyrophosphate, 5 mmol/L ethylenediaminetetraacetic acid
(EDTA), and 2 mmol/L sodium orthovanadate]. The ly-
sates were first precleared with Pansorbin (Calbiochem,
San Diego, CA, USA), then lysates containing equal
amounts of protein (0.5 mg) were incubated with poly-
clonal anti-Met antibody (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) at 4C for 2 hours. The resulting
immune complexes were collected by precipitation with
Pansorbin, washed three times with immunoprecipiation
buffer, resuspended in 1  Laemmli electrophoresis
buffer, and heated at 95C for 5 minutes. Proteins were
resolved by electrophoresis on 4% to 12% sodium dodecyl
sulfate-polyacrylamide gel elctrophoresis (SDS-PAGE)
gels, and transferred to nitrocellulose membranes. Tyro-
sine phosphorylation of the receptors was visualized by
Western blotting of the membranes with monoclonal anti-
phosphotyrosine antibody (PY99, 1:500) (Santa Cruz Bio-
technologies) and horseradish peroxidase-coupled sec-
ondary antibody, using the enhanced chemiluminescence
(ECL) detection system (Amersham, Buckinghamshire,
UK). In parallel experiments, blots were treated with anti-
Met antibody (1:200) to confirm equal loading of samples.
Assessment of mitogen-activated protein
kinase phosphorylation
Phosphorylation of the mitogen-activated protein ki-
nase (MAPK) extracellular signal-related protein kinase
(ERK)1/2, p38 MAPK, and c-Jun NH2 terminal kinase
(JNK) were assessed by Western blot. Quiescent cells
were stimulated with HGF (20 ng/mL) for the indicated
times, then the reactions were stopped by the addition
of ice-cold 1  Laemmli electrophoresis buffer. Proteins
were resolved by electrophoresis on 12% SDS-PAGE
gels, then phosphorylated MAPKs were detected using
antiphospho-ERK1/2, antiphospho-p38 MAPK, and anti-
phospho-JNK antibodies (Cell Signaling, Beverly, MA,
USA). The relative intensities of the bands were assessed
using computer densitometry software (Scion Image,
Frederick, MD, USA).
Proteoglycan synthesis assays
Synthesis of cell-associated and medium-secreted pro-
teoglycan was determined as described by us previously
[15, 16]. Cells in 24-well plates were made quiescent in
serum-free media for 48 hours. Following serum depri-
vation, cultures were incubated in DMEM containing
3H-glucosamine (2 Ci/mL) or sulfate-free medium con-
taining 35S-sulfate (5 Ci/mL) in the presence of HGF
(20 ng/mL unless otherwise stated) for 48 hours. The
medium was harvested and 300 L of the supernatant
was incubated with 25 L of 25 mmol/L MgSO4, and
120 L of 2.5% cetylpyridinium chloride (CPC) in the
presence of 5 g of carrier chondroitin sulfate for 1 hour
at 37C. Precipitated proteoglycans were collected on
nitrocellulose filters by vacuum filtration, washed with
1.0% CPC in 20 mmol/L NaCl and radiocounted in a
liquid scintillation counter. In some experiments, sam-
ples were treated overnight at 37C with chondroitin-
aseABC (10 mU) in 33 mmol/L Tris HCl, 33 mmol/L
sodium acetate, 80 g/mL bovine serum albumin (BSA)
(pH 8.0), or chondroitinase AC (10 mU) in 33 mmol/L
Tris HCl, 80 g/mL BSA (pH 6.0), or heparitinase III
(10 mU) in 100 mmol/L sodium acetate, 10 mmol/L cal-
cium acetate (pH 7.0) prior to CPC precipitation. For
determination of cell-associated proteoglycan synthesis,
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the cell layers were rinsed with PBS and lysed in 1 mol/L
NaOH. A total of 300 L of each sample were neutral-
ized with 2 N acetic acid, and digested with Pronase E
(1 mg/mL) at 55C for 18 hours. After addition of chon-
droitin sulfate (100 g/mL) as a carrier, cell-associated
proteoglycans were precipitated for 3 hours at 37C with
1% CPC in 20 mmol/L NaCl. The precipitate was collected
on nitrocellulose filters and treated as described above.
Ion exchange chromatography
To separate proteoglycans in the media on the basis
of differences in charge density, ion exchange chroma-
tography was performed as described previously using
DEAE-Sephacel (Amersham) [15, 16]. After application
of media containing 35S-sulfate–labeled proteoglycans
from control and HGF-treated cells, unbound radioactiv-
ity was removed from the column by washing with 30 mL
of wash buffer [8 mol/L urea, 50 mmol/L Tris (pH 7.5),
2 mmol/L EDTA, 0.1 mol/L NaCl, 0.5% Triton X-100].
Bound radioactivity was eluted with a NaCl gradient (0.1
to 0.7 mmol/L in the same buffer) and the radioactivity
in the collected fractions were quantified by scintillation
counting.
Northern blot analysis
Total RNA was purified by the acid guanidine-phenol-
chloroform method [12] and quantified by measurement
of absorbance of 260 nm in a spectrophotometer. Total
RNA (20g) was denatured with formamide and formal-
dehyde at 65C for 10 minutes and fractionated by elec-
trophoresis through a 1.0% formaldehyde-agarose gel.
RNA was stained with ethidium bromide to verify integ-
rity and equal loading, transferred to a nylon filter (Pall
BioSupport, East Hills, NY, USA), then cross-linked
using an ultraviolet irradiator (Stratagene, La Jolla, CA,
USA). Prehybridization was conducted at 42C for 2
hours in a buffer containing 6  standard sodium citrate
(SSC) [0.9 mol/L sodium chloride, 0.09 mol/L sodium
citrate (pH 7.0)], 5  Denhardt’s solution [0.1% (wt/
vol) polyvinylpyrrolidone, 0.1% (wt/vol) ficoll type 400,
and 0.1% (wt/vol) BSA], 50% formamide, 0.1% SDS,
and sheared, denatured salmon sperm DNA (100g/mL).
The cDNA probe for biglycan [17] was generously pro-
vided by Dr. Dreher (Weis Center for Research, Dan-
ville, PA, USA). The probe for glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was obtained from
Clontech (Palo Alto, CA, USA). Probes were radio-
labeled with -32P deoxycytidimine triphosphate (dCTP)
by the random primer synthesis method (RadPrime
DNA Labeling System, Gibco-BRL, Grand Island, NY,
USA). After hybridization, the filter was washed in 0.2
SSC, 0.1% SDS at 42C. Bands were visualized, and
incorporated radioactivity was quantified by scanning
with a laser image analyzer (model BAS 2000, Fuji Film,
Tokyo, Japan).
RT-PCR
RT-PCR was performed as described by us previously
[16]. One microgram total RNA was reverse transcribed
in a reaction mixture containing 10 mmol/L Tris HCl
(pH 8.3), 50 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L
desoxynucleoside triphosphate (dNTP), 1 U RNase in-
hibitor, 2.5 mol/L (50 pmol) random hexamers and 2.5
U Moloney murine leukemia virus reverse transcriptase
in a volume of 20 L. The reverse-transcribed product
was amplified with proteoglycan core protein sense and
antisense primers in a reaction mixture containing 10
mmol/L Tris HCl (pH 8.3), 50 mmol/L KCl, 2 mmol/L
MgCl2, 0.2 mmol/L dNTP, 15 pmol of each primer, 5 Ci
32P dCTP, and 2.5 U Taq polymerase using a Perkin-
Elmer-Cetus Thermal Cycler (Perkin-Elmer, Norwalk,
CT, USA) for 24 cycles. The sequences of the primers
for biglycan, decorin, versican, perlecan, and GAPDH
were as reported previously [16, 18]. Preliminary experi-
ments confirmed that the amplifications were performed
in the linear phase of the amplification cycle. In some
experiments, reaction products were subcloned into the
plasmid pCDNA3.1His/Topo (Invitrogen, Groningen,
The Netherlands) and sequenced using an automated
sequencer. Reaction products were resolved by electro-
phoresis through 8% polyacrylamide gels. Gels were
dried using a gel dryer prior to imaging using a laser
image analyzer.
Western blot analysis of proteoglycan core proteins
Western blot analysis of proteoglycan core proteins
in the media of NHF cells treated with HGF (20 ng/mL)
was performed after chondroitinase ABC digestion as de-
scribed previously [16] using antihuman biglycan (LF-51)
and antihuman decorin (LF-136) antibodies [19, 20],
which were generously provided by Dr. Fisher (National
Institute of Dental and Craniofacial Research, Bethesda,
MD, USA).
Transient transfection and luciferase assays
Plasmids containing various lengths of the 5-flanking
region of the human biglycan gene cloned upstream of
the luciferase gene in vector pGL2-Basic (Promega,
Madison, WI, USA) [21] were generously provided by
Dr. Ungefroren (University of Hamburg, Germany).
The constructs used were Bgn (1212,	42), Bgn (686,
	42), Bgn (153,	42), Bgn (78,	42), and Bgn (46,
	42). The numbers in parentheses refer to the positions
of the 5- and 3-nucleotides relative to the major tran-
scription start site (5 end of exon 1) of the biglycan
gene. To assess the promoter activity of luciferase con-
structs with and without HGF treatment, NRK-49F cells
in 24-well plates were transfected with various biglycan
promoter luciferase plasmids (0.5 g) using lipofectam-
ine plus (Gibco-BRL) as recommended by the manufac-
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turers. Some of the cells were treated with HGF (20
ng/mL) after completion of the transfection procedure.
A Renilla luciferase construct (pRL-TK) was used to
normalize for changes in transfection efficiency, and the
luciferase activities were assessed 24 hours after transfec-
tion by the dual luciferase assay (Promega) exactly as
recommended by the manufacturer.
Thymidine incorporation studies and enzyme-linked
immunosorbent assay for active TGF-1
Subconfluent NRK-49F cells in 24-well plates were
made quiescent by treating with serum-free medium for
48 hours. TGF- 1 and biglycan were preincubated to-
gether at 37C for 24 hours, then applied to the quiescent
cells. After 24 hours, 3H- thymidine (1 Ci/mL) was
added, and the cells were harvested after a further 24
hours for the assessment of thymidine incorporation by
trichloroacetic acid (TCA) precipitation [22]. The activ-
ity of TGF-1 in the culture medium in the presence or
absence of biglycan was assessed by measurement of
active TGF-1 using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (R&D Sys-
tems, Minneapolis, MN, USA), exactly as recommended
by the manufacturer. Total TGF-1 in the same samples
was estimated after acid activation of latent TGF-1
following the manufacturer’s protocols.
Statistics
Results are expressed as the mean 
 SEM. Statistical
comparisons were made by analysis of variance (AN-
OVA) followed by Scheffe’s F test. P values less than
0.05 were considered statistically significant.
Materials
Cell culture materials, radioisotopes, and electropho-
resis materials were obtained from Gibco-BRL, Amer-
sham, and BioRad, respectively. Recombinant human
TGF-1 was obtained from R&D Systems. Other re-
agents, including biglycan purified from bovine articular
cartilage, were obtained from Sigma Chemical Co. (St.
Louis, MO, USA), unless otherwise stated.
RESULTS
Analysis of c-Met expression and activation in
interstitial fibroblasts
To examine if rat interstitial fibroblasts (NRK-49F)
express the c-Met receptor, RT-PCR was performed us-
ing the primers and protocols described by Oh et al [13].
As shown in Figure 1A, a 725 bp band corresponding
to reverse transcribed and amplified c-Met mRNA was
readily detectable, whereas the band was not seen in the
absence of reverse transcriptase treatment, suggesting
expression of c-Met mRNA. Similar results were seen
with primary cultures of human fibroblasts (NHF cells).
Fig. 1. Expression and activation of hepatocyte growth factor (HGF)
receptor c-Met in NRK-49F and neonatal human fibroblast (NHF)
cells. (A ) Reverse transcription-polymerase chain reaction (RT-PCR)
analysis of c-Met mRNA. Total RNA from NRK-49F or neonatal hu-
man fibroblast (NHF) cells were treated with or without RT, then PCR
was performed using primers specific for c-Met mRNA. (B) Activation
of c-Met by HGF. NRK-49F cells were treated for the indicated times
with HGF, then phosphorylation of c-Met was examined by immunopre-
cipitation with anti-Met antibody followed by immunoblot with antiphos-
photyrosine antibody (left panel), or anti-Met antibody (right panel) as
described in the Methods section.
To confirm that the receptors were functionally active,
cells were stimulated with HGF, and the tyrosine phos-
phorylation of the receptors after agonist treatment was
examined by immunoprecipitation with c-Met antibody
followed by immunoblot with antiphosphotyrosine anti-
body. As shown in Figure 1B, treatment with HGF re-
sulted in an increase in the phosphorylation of immuno-
precipitated c-Met at 5 minutes.
Effects of HGF on phosphorylation of ERK1/2, p38
MAPK, and JNK in interstitial fibroblasts
To examine the effects of HGF on phosphorylation
of different MAPKs, cells were treated with HGF, then
activation of MAPK was assessed by examination of phos-
phorylated MAPK by Western blot analysis. As shown
in Figure 2, treatment with HGF resulted in a marked
(five- to tenfold) increase in phosphorylation of ERK1/2
and p38 MAPK, without a major change in JNK.
Effects of HGF on proteoglycan synthesis in
interstitial fibroblasts
Next, the effects of HGF on proteoglycan synthesis
were examined. As shown in Figure 3, treatment of
NRK-49F cells with HGF resulted in a significant (P 
0.01) increase in proteoglycan synthesis. A time- and
dose-dependent increase in both cell-associated and se-
creted proteoglycan synthesis was seen. In order to char-
acterize the subclass of the proteoglycans in control and
HGF-treated samples, conditioned media were treated
with the enzymes chondroitinase ABC, chondroitinase
AC, and heparitinase prior to CPC precipitation. Treat-
ment of cells with HGF resulted predominantly in an
Kobayashi et al: HGF regulation of proteoglycans 1183
Fig. 2. Effects of hepatocyte growth factor
(HGF) on phosphorylation of mitogen-acti-
vated protein kinase (MAPK) family proteins
in NRK-49F cells. Quiescent cells were treated
with HGF (20 ng/mL) for the indicated times,
then phosphorylation of extracellular signal-
related protein kinase (ERK) 1/2 and p38
MAPK, but not of c-Jun NH2 terminal kinase
(JNK) was assessed using specific antibodies
as described in the Methods section. (A ) Rep-
resentative image of Western blot. (B ) Re-
sults of densitometric analysis.
Fig. 3. Time course and dose dependency of
hepatocyte growth factor (HGF)-induced
changes in proteoglycan synthesis in NRK-
49F cells. Quiescent cells were treated with 20
ng/mL HGF for various times (A ) or various
doses (B ) of HGF for 48 hours, then proteo-
glycan synthesis in the cell layer and media
was assayed as described in the Methods sec-
tion. Results shown are the mean
 SEM (N
4 per assay point). *P 0.05 vs. control; **P
0.01 vs. control.
increase in chondroitinase ABC–sensitive proteoglycans
(Table 1), without a major change in the heparitinase-
sensitive proteoglycans.
In order to confirm these results, characterization of
the proteoglycan subclass was also performed by ion ex-
change chromatography using DEAE-Sephacel (Fig. 4).
In the supernatants from both control and HGF-treated
samples, incorporated 35S-sulfate radioactivity eluted from
the ion exchange column predominantly at two peaks.
The counts from peak I and II were attenuated by pre-
treatment with heparitinase and chondroitinase ABC,
respectively, as reported previously [15], confirming that
these peaks contained predominantly heparan sulfate
proteoglycans (HSPG) and chondroitin sulfate proteo-
glycans (CSPG)/dermatan sulfate proteoglycans (DSPG).
A clear increase in peak II was seen in the HGF-treated
samples, whereas no major changes in peak I were ob-
served, suggesting an increase in CSPG/DSPG consistent
with the results of the enzyme digestion experiments.
Effects of MEK inhibitor and p38 MAPK inhibitor on
the HGF-mediated increase in proteoglycan synthesis
To examine the signal transduction mechanisms in-
volved in the increase in proteoglycan synthesis mediated
by HGF, cells were pretreated with the MEK inhibitor
PD98059 or the p38 MAPK inhibitor SB203580 in order
to inhibit the ERK1/2 and p38 MAPK pathways, respec-
tively. As shown in Figure 5, the HGF-mediated in-
creases in proteoglycan synthesis in both the media and
cell layers were attenuated by treatment with either the
MEK or p38 MAPK inhibitors, suggesting that both
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Table 1. Analysis of proteoglycan subtype synthesis in media from NRK-49F cells with and without HGF treatment
Incorporation cpm/lg protein
HGF () HGF (	)
3H-glucosamine 35S-sulfate 3H-glucosamine 35S-sulfate
Chondroitinase ABC-sensitive incorporation 331
77 198
44 949
235a 405
30a
Chondroitinase AC-sensitive incorporation 207
71 94
30 380
116 141
51
Heparitinase-sensitive incorporation 61
29 29
14 82
20 42
21
Abbreviations are: NRK-49F, rat renal interstitial fibroblasts; HGF, hepatocyte growth factor.
Results shown are mean 
 SEM (N  6).
a P  0.05 vs. HGF ()
Fig. 4. Analysis of proteoglycans in media from control and hepatocyte
growth factor (HGF)-treated NRK-49F cells by DEAE-Sephacel ion
exchange chromatography.
ERK1/2 and p38 MAPK pathways were involved in the
changes in proteoglycan synthesis mediated by HGF.
Effects of HGF on proteoglycan core
protein expression
To examine if the changes in proteoglycan synthesis
mediated by HGF involved changes in proteoglycan core
protein mRNA, Northern blot analysis was performed to
assess changes in the major proteoglycan core proteins.
Since the signals obtained by Northern blot were low in
the case of decorin, versican, and perlecan (data not
shown), the mRNA for these core proteins were assessed
by RT-PCR. Previous studies from our group have con-
firmed a close correlation between the results of RT-
PCR and Northern blot analysis [16, 18]. Treatment of
NRK-49F cells with HGF caused significant (P  0.05)
increases in biglycan and decorin mRNA, whereas no
significant change was seen in the case of versican and
perlecan. To confirm these findings, expression of the
proteoglycan core proteins decorin and biglycan in con-
trol and HGF-treated samples were examined by West-
ern blot analysis. These experiments were performed
using NHF, since the antibodies used (LF-51 and LF-
136) were raised against the human core proteins. The
antibodies showed some cross-reactivity toward purified
bovine biglycan and decorin, which were run in parallel
as positive controls. Consistent with the result of North-
ern blot analysis and RT-PCR, expression of biglycan
and decorin was increased in HGF-treated samples com-
pared to control cells (Fig. 6B). Moreover, the increases
in biglycan and decorin induced by HGF were attenuated
by pretreatment with the MEK inhibitor PD98059 and
the p38 MAPK inhibitor SB203580, suggesting that the
MEK and p38 MAPK pathways affect both biglycan and
decorin.
Effects of HGF on biglycan promoter activity
In order to examine the mechanisms of the HGF-
induced increase in biglycan mRNA, NRK-49F cells
were transfected with biglycan promoter constructs using
lipofectamine, and promoter activity with or without
HGF treatment was assessed by the dual luciferase assay.
As shown in Figure 7, HGF caused a significant increase
(threefold) in the promoter activity of the biglycan
construct Bgn (1212, 	42). In contrast, no significant
increase in promoter activity was induced by HGF in
the case of the truncated constructs Bgn (686, 	42),
Bgn (153,	42), Bgn (78,	42), and Bgn (46,	42).
These results support the data from the Northern blot
analysis, and suggest transcriptional control at a region
between –686 and –1212 as a potential mechanism for the
increased gene expression of biglycan mediated by HGF.
Effects of biglycan and basal and TGF-–stimulated
proliferation of interstitial fibroblasts
At present, the effects of biglycan on growth of fibro-
blasts are unclear. Therefore, in order to clarify these
actions, cells were stimulated with biglycan with or with-
out TGF-1, and the effects on DNA synthesis were as-
sessed by thymidine incorporation studies. As shown in
Figure 8A, biglycan alone did not cause a significant
change in thymidine incorporation by these cells. In con-
trast, biglycan pretreatment of TGF-1 resulted in a sig-
nificant reduction in thymidine incorporation compared
to cells treated with TGF- 1 in the absence of biglycan.
The effects of biglycan were dose-dependent, as shown
in Figure 8B. In further studies, the activity of TGF-1
(1 ng/mL) pretreated with or without biglycan (20 nmol/L)
Kobayashi et al: HGF regulation of proteoglycans 1185
Fig. 5. Effects of MAPK/ERK kinase (MEK)
inhibitor and p38 mitogen-activated protein
kinase (MAPK) inhibitor on hepatocyte growth
factor (HGF)-induced changes in cell-asso-
ciated and secreted proteoglycan synthesis
in NRK-49F cells. Quiescent cells were pre-
treated with (upper panel) the MEK inhibitor
PD98059 (PD 15:15mol/L; PD 30:30mol/L),
or (lower panel) the p38 MAPK inhibitor
SB203580 (SB 25:25 mol/L; SB 37.5:37.5
mol/L) or vehicle [dimethyl sulfoxide
(DMSO)], prior to stimulation with 20 ng/mL
HGF for 48 hours, then proteoglycan synthesis
in the cell layer (A ) and the media (B ) was
assayed as described in the Methods section.
Results shown are the mean 
 SEM (N  4
per assay point). **P  0.01 vs. the respective
groups; #P  0.05 vs. control HGF() (col-
umn 1).
Fig. 6. Effects of hepatocyte growth factor
(HGF) on proteoglycan core protein expres-
sion. (A ) NRK-49F cells were treated with
HGF (20 ng/mL) for the indicated times, and
levels of biglycan, decorin, versican, and per-
lecan mRNA were assessed by Northern blot
analysis (biglycan), or reverse transcription-
polymerase chain reaction (RT-PCR) (de-
corin, versican, perlecan). Representative im-
age of Northern blot or RT-PCR assay (left
panels). Results of laser densitometric quanti-
tation (right panels). Results shown are the
mean 
 SEM (N  4 per assay point). *P 
0.05 vs. control; **P  0.01 vs. control. (B )
Neonatal human fibroblast (NHF) cells were
pretreated with the MEK inhibitor PD98059
(PD 30 mol/L), or the p38 MAPK inhibitor
SB20350 (SB 37.5 mol/L), or vehicle [di-
methyl sulfoxide (DMSO)], then incubated
with or without HGF (20 ng/mL) for 72 hours,
and levels of biglycan and decorin proteins in
the media were assessed by Western blot as
described in the Methods section. PC, positive
control; 10 pmol of purified bovine biglycan
or decorin were treated with chondroitinase
ABC and run as positive controls. Arrows
show the position of molecular size markers.
was assessed using an ELISA for active TGF-1. No sig-
nificant changes in either active TGF-1 (without bigly-
can, 0.87
 0.11 ng/mL; with biglycan, 1.14
 0.11 ng/mL;
N  4) or total (active 	 latent) TGF-1 (without bigly-
can, 1.27
 0.03 ng/mL; with biglycan, 1.31
 0.04 ng/mL;
N  4) were detectable in the culture media by ELISA.
DISCUSSION
The growth factor HGF is receiving increasing interest
as a potential therapeutic candidate for the treatment of
renal disease. It has been shown that the actions of HGF
are mediated through a specific receptor c-Met [2]. This
receptor is a transmembrane protein possessing an intra-
cellular tyrosine kinase domain, and is activated by HGF
leading to autophosphorylation of the receptor. Potential
targets for HGF action in the kidney include components
of the renal glomeruli (endothelial cells, mesangial cells,
and epithelial cells), as well as tubular epithelial cells
in the tubulointerstitial region [2, 3]. Our results using
fibroblasts from two different sources suggested that
these cells also express the c-Met mRNA. Moreover, we
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Fig. 7. Effects of hepatocyte growth factor
(HGF) on biglycan promoter activity in NRK-
49F cells. Cells were transfected with the indi-
cated biglycan promoter-luciferase constructs,
then treated with or without HGF (20 ng/mL)
prior to assay of luciferase activity as de-
scribed in the Methods section. Results shown
are the mean
 SEM (N  4 per assay point).
*P  0.05 vs. HGF ().
Fig. 8. Inhibition of transforming growth
factor-1 (TGF-1)–mediated proliferative
responses by biglycan in NRK-49F cells. Cells
were stimulated with various concentrations
of TGF- 1 together with a fixed concentra-
tion of biglycan (20 nmol/L) (A ) or a fixed
concentration of TGF- 1 (1 ng/mL) together
with various concentrations of biglycan (B ),
then thymidine incorporation was assayed as
described in the Methods section. *P  0.05
vs. the respective groups; **P  0.01 vs. the
respective groups.
found that HGF can interact with the expressed recep-
tors resulting in their phosphorylation and can also acti-
vate ERK1/2 and p38 MAPK, suggesting signal pathway
mechanisms similar to those found in other cells such as
lung adenocarcinoma cells [23]. The extension of poten-
tial targets of HGF in the kidney to fibroblasts may be
important since these cells play a central role in the
processes of interstitial fibrosis.
Previous studies from our and other laboratories have
implicated changes in proteoglycan synthesis as an im-
portant factor in the actions of vasoactive peptides, hor-
mones, and their antagonists [15, 16, 24]. These glycopro-
teins consist of a core protein covalently bound to one
or more glycosaminoglycan (GAG) side chains [24]. The
proteoglycans found in the kidney can be classified ac-
cording to the composition of the GAG side chains into
CSPG, DSPG, and HSPG. These proteoglycans have
been implicated in many of the crucial steps connected
with renal fibrosis, including the control of collagen de-
position, and regulation of growth factors.
Since HGF may be an important modulator of fibrosis
in the renal interstitium, we examined the effects of
HGF on proteoglycan synthesis in the renal interstitial
fibroblasts, and found that HGF can enhance the synthe-
sis of both secreted and cell-associated proteoglycan syn-
thesis. Because both ion exchange chromatography and
enzyme digestion studies suggested subtype-specific reg-
ulation of proteoglycans by HGF, we further character-
ized the changes in proteoglycan core protein expression
and found evidence for up-regulation of the core proteins
biglycan and decorin. Since these two proteoglycans are
both of the CSPG/DSPG class, the results of these studies
at the molecular (mRNA) level were consistent with
the biochemical findings. Confirmatory Western blots
of proteoglycan core proteins were also performed on
human cells (NHF) because the antibodies used (LF-51
and LF-136) were raised against the human proteins,
and these results were also consistent with the results
using NRK-49F cells.
Both biglycan and decorin are members of the small
leucine-rich proteoglycan (SLRP) family, and are prefer-
entially expressed in the renal interstitium [25, 26]. These
proteoglycans are noted for their ability to interact with
growth factors and cytokines. Decorin is of clinical inter-
est, first, because it has been shown to be able to inacti-
vate TGF- both in vitro and in vivo, and second, be-
cause expression of decorin in the renal interstitum has
been suggested to be a prognostic marker for renal dis-
ease progression [9, 10, 27]. Hildebrand et al [28] showed
that both biglycan and decorin can bind to TGF- and
can inhibit binding of the growth factor to Mv 1 Lu cells.
Of interest, the binding between TGF- and biglycan or
decorin was increased by removal of the proteoglycan
GAG side chains, suggesting that the interaction is medi-
ated through the core proteins [9, 28]. In this study, we
determined whether biglycan can modulate the actions
of TGF-1 in NRK-49F fibroblasts and found that bigly-
can alone does not cause a significant change in fibroblast
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proliferation, but showed the ability to attenuate the
proliferative actions of TGF-1 on fibroblasts. This find-
ing is relevant since TGF-1 is thought to play a central
role in the progression of renal disease, and the long-
term overproduction of this growth factor is thought to
be a major event in the pathogenesis of interstitial fibro-
sis [29]. TGF- has been shown to enhance the expres-
sion of biglycan in different cells, including fibroblasts,
arterial smooth muscle cells, and mesangial cells [30–32].
These findings are compatible with the view that TGF-
–induced up-regulation of biglycan may act as a nega-
tive feedback loop to limit excessive action of this growth
factor in these tissues, but further in vivo studies are
required in this area.
As mentioned in the introduction, data from recent
studies have suggested that HGF may have antagonistic
actions to TGF-, particularly in terms of renal fibrosis.
Concerning the mechanisms of the interaction between
HGF and TGF-, it has been suggested that HGF may
exert at least a part of its actions via down-regulation
of TGF- itself [5], as well as by up-regulation of extra-
cellular matrix–degrading enzymes such as matrix metal-
loproteinase (MMP)-1, and MMP-9 [33]. The results of
this study suggest the possibility that HGF may also in-
teract with TGF- in the renal interstitium by regulating
TGF-–modulatory proteoglycans.
Concerning potential mechanisms of the HGF-induced
increase in gene expression of biglycan, our results sug-
gested the involvement of transcriptional control at a re-
gion between –1212 and –686 relative to the transcription
start site. Of interest, this region contains several puta-
tive regulatory elements, including interleukin-6 (IL-6)
responsive elements, CCAAT/enhancer-binding protein
(C/EBP), and activator protein-2 (AP-2) [21]. Potential
transcription factors which have been reported to be af-
fected by HGF include ETS1, nuclear factor-B (NK-B),
AP-1, and activating transcription factor-2 (ATF-2)
[34, 35], but the possibility that HGF could act by a
different transcription factor cannot be excluded and
requires further assessment.
HGF is currently anticipated to be of potential thera-
peutic benefit for the treatment of renal diseases, and
indeed clinical trials using HGF for the treatment of
vascular disease have already been started [36]. It is
relevant that HGF can up-regulate decorin because de-
corin itself is a candidate for treatment of chronic renal
failure [10, 11]. Although most in vivo studies have
shown that HGF can reduce renal interstitial fibrosis
[5–7], one report using transgenic mice that overexpress
HGF noted detrimental effects such as increased focal
segmental glomerulosclerosis, as well as renal hyperpla-
sia and renal cysts [37]. Therefore, further studies are
required to clarify the advantages and disadvantages of
treatment strategies using HGF alone, compared with
direct treatment with TGF-–inhibitory proteoglycans
(biglycan or decorin) for the treatment of progressive
renal disease.
CONCLUSION
The results of this study suggest (1) that renal intersti-
tial fibroblasts express the HGF receptor, which under-
goes tyrosine phosphorylation after agonist treatment;
(2) that HGF can activate ERK and p38 MAPK path-
ways in these cells; (3) that HGF up-regulates proteogly-
cans of the CSPG/DSPG class, namely biglycan and de-
corin; and (4) that the HGF-mediated effects involve
both ERK and p38 MAPK-mediated pathways, as well
as subtype-specific increase in gene expression through
transcriptional control. Since proteoglycans have impor-
tant growth-regulatory effects in the renal interstitium,
these results may be important for furthering our under-
standing of how HGF can be of therapeutic value in
inhibiting the progression of renal interstitial changes.
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